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ABSTRACT
Purpose To describe changes in intraocular pressure
(IOP) in the ‘alternative treatments to Inhibit VEGF in
Age-related choroidal Neovascularisation (IVAN)’ trial
(registered as ISRCTN92166560).
Design Randomised controlled clinical trial with
factorial design.
Participants Patients (n=610) with treatment naïve
neovascular age-related macular degeneration were
enrolled and randomly assigned to receive either
ranibizumab or bevacizumab and to two regimens,
namely monthly (continuous) or as needed
(discontinuous) treatment.
Methods At monthly visits, IOP was measured
preinjection in both eyes, and postinjection in the study
eye.
Outcome measures The effects of 10 prespeciﬁed
covariates on preinjection IOP, change in IOP
(postinjection minus preinjection) and the difference in
preinjection IOP between the two eyes were examined.
Results For every month in trial, there was a
statistically signiﬁcant rise in both the preinjection IOP
and the change in IOP postinjection during the time in
the trial (estimate 0.02 mm Hg, 95% CI 0.01 to 0.03,
p<0.001 and 0.03 mm Hg, 95% CI 0.01 to 0.04,
p=0.002, respectively). There was also a small but
signiﬁcant increase during the time in trial in the
difference in IOP between the two eyes (estimate
0.01 mm Hg, 95% CI 0.005 to 0.02, p<0.001). There
were no differences between bevacizumab and
ranibizumab for any of the three outcomes (p=0.93,
p=0.22 and p=0.87, respectively).
Conclusions Anti-vascular endothelial growth factor
agents induce increases in IOP of small and uncertain
clinical signiﬁcance.
Trial registration number ISRCTN92166560.
INTRODUCTION
A rise in intraocular pressure (IOP) was not observed
in the initial ANCHOR and MARINA trials of
agents that inhibit vascular endothelial growth
factor (VEGF); but subsequently small clinical series
have reported rises in IOP in around 3%1 2 to 12%3
in treated eyes with similar rates observed in the
fellow eye.4 Concerns have been raised that there is
a cumulative effect on pressure rise after multiple
intraocular injections of anti-VEGF agents,5–7
although this ﬁnding has not been consistently repli-
cated.8 Mechanisms that have been postulated to
explain this IOP rise include the volume effect of the
injection,9 the particular properties of the agent
(bevacizumab is a full length antibody with an Fc
fragment which may induce a trabeculitis,10–12 and/
or the presence of particulates) or the inhibition of
VEGF within the trabecular meshwork leading to
reduced facility of aqueous outﬂow
Accordingly, we undertook an exploratory analysis
of the alternative treatments in the inhibition of
VEGF in age-related choroidal neovascularisation
(IVAN) clinical trial dataset. The IVAN trial (regis-
tered ISRCTN92166560) was a randomised con-
trolled trial with a 2×2 factorial design comparing
ranibizumab with bevacizumab and monthly (con-
tinuous) with as needed (discontinuous) treatment
strategies.
We hypothesised that:
▸ Preinjection IOP would increase with the number
of injections administered.
▸ The size of the postinjection pressure ‘spike’
would provide an estimate of the functioning of
the trabecular meshwork and facility of aqueous
outﬂow.
As IOP was measured in both eyes at every visit,
the difference in IOP between study and fellow
eyes over time could also be examined, allowing
the fellow eye to act as a within-subject control for
a trend in preinjection IOP.
MATERIALS AND METHODS
Patients
Patients over the age of 50 with active, treatment
naive neovascular age-related macular degeneration
(nAMD) were recruited. Those with ﬁeld defects
attributable to glaucoma were excluded (guidance
rather than formal exclusion—there being no reli-
able way to distinguish ﬁeld defects due to glau-
coma from those due to macular degeneration) but
those with a history of ocular hypertension, or
glaucoma per se, were not (ie, these patients are
best considered as having preperimetric glaucoma).
The CONSORT diagram is reported elsewhere.13
The full list of inclusion and exclusion criteria
is provided as online supplementary ﬁle 1. A UK
National Health Service Research Ethics
Committee approved the trial (07/NIR03/37).
Patients with glaucoma were identiﬁed on the basis
of either having had glaucoma surgery (of which
there were none) or prescription of topical pressure
lowering medications (46 patients). This criterion
does not distinguish between patients with ocular
hypertension and those with glaucoma and so these
two groups were combined into a single group and
labelled as glaucoma for the analyses. And it should
be noted that neither gonioscopy nor central
corneal thickness measurements were performed.
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IOP measurements
The IOP was measured monthly using Goldmann applanation
tonometry in both eyes prior to treatment and in the study eye
after injection if treated. Two readings were made and if more
than 2 mm apart, a third reading was taken. Visit IOP for each
eye was the mean of the two or the median of the three.
Equipment was calibrated at least twice annually.
The clinicians were not masked to which was the study eye
for these measurements but were doing it for safety monitoring
only and no hypothesis was even discussed until after data col-
lection was complete.
Study outcomes
Three outcomes were prespeciﬁed in an analysis plan. These
were as follows:
1. Postinjection IOP ‘spike’ (ie, postinjection IOP minus prein-
jection IOP) in the study eye, at visits where injections were
administered.
2. Preinjection IOP in the study eye.
3. The difference in preinjection IOP between the study and
fellow eyes (ie, study eye preinjection IOP minus fellow eye
preinjection IOP).
Statistical analysis
The analyses used data from all available IVAN study visits (up
to 25 visits). Ten covariates were prespeciﬁed in the analysis
plan: months in study, months since last injection, mean arter-
ial blood pressure, study drug, cataract surgery, glaucoma, age
at randomisation, gender, baseline preinjection IOP in the
study eye (outcomes 1 and 3) and the time between the injec-
tion and the postinjection IOP measurement (outcome 1). We
treated time in trial as a proxy for number of injections (adjust-
ing for time since last injection) since the two were strongly
correlated. Linear mixed modelling was used to analyse the
three study outcomes; intercept and ‘months in trial’ terms
were ﬁtted as random effects in all three models. For the ana-
lyses of preinjection IOP, namely outcomes 2 and 3, the base-
line measurements of each outcome were modelled jointly with
the subsequent values to avoid the need to exclude cases with
missing baseline values. Model validity was checked and outly-
ing values were excluded. Linearity assumptions were also
checked and when non-linear, the data were grouped into cat-
egories. All covariates were retained in the models regardless
of their signiﬁcance. Results are reported as effect estimates
with 95% CIs. Two-sided p values <0.05 are considered statis-
tically signiﬁcant.
IOP was measured at every visit and the amount of missing
data was low (less than 5% of attended visits; a further 13% of
visits were not attended13). However, blood pressure was only
measured every 3 months. Plots of the mean arterial pressure sug-
gested that the pressure did not change much over time, so values
were interpolated for the visits where it was not measured.
Cataract surgery was identiﬁed by the phakic status of the
eye. A time-dependent indicator variable was ﬁtted to denote
when surgery took place. The impact of having surgery in both
eyes was tested by adding an interaction term to the model. This
term was retained if signiﬁcant at the 5% level. As for cataract
surgery, a time-dependent indicator variable was ﬁtted to
describe when patients’ were identiﬁed as glaucomatous during
time in the trial.
Baseline preinjection IOP in the study eye, study drug, age at
randomisation and gender did not vary across visits.
RESULTS
All 610 participants in the IVAN study cohort were included in
this analysis.13 There were 13 371 study visits including baseline
and injections were administered at 10 160 of these visits.
The median duration of active participation in the trial was
23.6 months (IQR 22.8 to 24.3), with a median time between
injections of 1.0 month (IQR 0.9 to 1.2). Baseline preinjection
IOP in the study eye was measured for 607/610 patients with a
median of 15 mm Hg (IQR 14 to 18). Glaucoma was present in
46/610 (7.5%) patients, and 219/610 (35.9%) patients were
pseudophakic/aphakic in at least one eye during the trial; the
majority of patients classiﬁed as glaucomatous (37/46 (80.4%)
or pseudophakic/aphakic (181/219 (82.6%) were classiﬁed as
such at trial entry. Participant demographics and ophthalmic
characteristics are summarised in table 1.
Participant age at randomisation was grouped into categories
as the relationship with outcomes was non-linear.
Outcome 1: spikes in postinjection IOP (postinjection IOP
minus preinjection IOP)
IOP was measured preinjection and postinjection for 10 009 of
the 10 160 (98.5%) injections and the median postinjection IOP
spike was +3 mm Hg (IQR 0 to 7).
Figure 1 shows the multivariable effect estimates (ie, adjusted
for other covariates in the model) for the covariates in the
model examining the factors associated with postinjection IOP
spike.
For every month in the trial, on average a patient’s postinjec-
tion IOP increased by 0.03 mm Hg (95% CI 0.01 to 0.04,
p=0.002). In addition, the longer the time interval between
injection administration and measurement of postinjection IOP,
the lower the IOP spike (−0.07 mm Hg/min).
Compared with no cataract surgery, the IOP spike was reduced
in cataract-operated study eyes (−1.00 mmHg, 95% CI −1.75 to
−0.25), but did not differ when fellow eyes only or both eyes had
experienced surgery (ﬁgure 1; test for eye interaction p=0.028).
Glaucoma in either eye increased the postinjection IOP spike
on average by 1.15 mm Hg. The relationship with age was non-
linear, but those aged 85 and above had the highest IOP spike
compared with the reference group of age 50–69 years.
Male patients had a larger postinjection IOP spike than females.
Months since last injection, mean arterial pressure and study
drug had no statistically signiﬁcant effect on postinjection IOP
change and the use of bevacizumab resulted in a non-signiﬁcant
but lower IOP spike than ranibizumab.
Outcome 2: preinjection IOP in the study eye during time in
study
IOP in the study eye was measured prior to injection at 13 281
(99.3%) of the 13 371 attended study visits. Data were available
for 607 patients at visit 0 and 514 patients at visit 24. The
median preinjection IOP across all visits was 15 mm Hg (IQR
13 to 18). Figure 2 shows the multivariable effect estimates for
covariates associated with preinjection IOP.
The average preinjection IOP in the study eye increased by
0.02 mm Hg/month. For every unit increase of mean arterial
pressure, preinjection IOP increased by 0.01 mm Hg. Compared
with no cataract surgery, study eye surgery signiﬁcantly reduced
preinjection IOP (−1.42 mm Hg), as did surgery on both eyes
(−0.79 mm Hg), but surgery on the fellow eye alone had no
effect (−0.18 mm Hg; test for eye interaction p=0.028).
Months since last injection, study drug, glaucoma status and
gender had no statistically signiﬁcant effect on preinjection IOP
(p=0.76, p=0.93, p=0.47 and p=0.32, respectively).
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Table 1 Summary of description of study population by glaucoma status
Patient characteristics n Glaucoma (n=46) No glaucoma (n=564) Overall (n=610)
Baseline
Drug (Avastin) 610 23 (50.0%) 273 (48.4%) 296 (48.5%)
Age (years) 610 80.0 (7.1) 77.5 (7.4) 77.7 (7.4)
50–69 2 (4.3%) 90 (16.0%) 92 (15.1%)
70–74 13 (28.3%) 97 (17.2%) 110 (18.0%)
75–79 8 (17.4%) 151 (26.8%) 159 (26.1%)
80–84 7 (15.2%) 132 (23.4%) 139 (22.8%)
85+ 16 (34.8%) 94 (16.7%) 110 (18.0%)
Gender (male) 610 18 (39.1%) 226 (40.1%) 244 (40.0%)
Preinjection IOP in study eye 607 16.8 (3.8) 15.3 (3.1) 15.4 (3.2)
Postinjection IOP change in study eye 594 2.8 (6.5) 3.1 (5.6) 3.1 (5.7)
Preinjection IOP eye difference (study eye IOP minus fellow eye IOP) 606 −0.7 (3.8) 0.0 (1.6) −0.1 (1.9)
During the trial
Any cataract surgery (pseudo/aphakic) 610 27 (58.7%) 192 (34.0%) 219 (35.9%)
In study eye only 7 (25.9%) 39 (20.3%) 46 (21.0%)
In fellow eye only 3 (11.1%) 29 (15.1%) 32 (14.6%)
In both eyes 17 (63.0%) 124 (64.6%) 141 (64.4%)
Months in trial 610 23.5 (23.0 to 24.5) 23.6 (22.8 to 24.3) 23.6 (22.8 to 24.3)
Months between injections 13 371 1.0 (0.9 to 1.8) 1.0 (0.9 to 1.2) 1.0 (0.9 to 1.2)
Time (min) between injection and postinjection IOP measurement 9966 25 (15 to 33) 21 (12 to 32) 22 (13 to 32)
Mean arterial pressure (mm Hg) 4795 95.4 (10.6) 96.3 (10.9) 96.2 (10.9)
Preinjection IOP in study eye 13 281 16.6 (4.0) 15.3 (3.3) 15.4 (3.4)
Postinjection IOP change in study eye 10 009 4.4 (6.9) 3.8 (5.3) 3.8 (5.4)
Preinjection IOP eye difference (study eye IOP minus fellow eye IOP) 13, 208 −0.4 (5.0) 0.1 (1.8) 0.5 (2.3)
At visit 24
Preinjection IOP in study eye 514 17.0 (4.0) 15.7 (3.3) 15.8 (3.4)
Postinjection IOP change in study eye (at visit 23) 358 5.1 (4.1) 3.9 (5.1) 4.0 (5.0)
Preinjection IOP eye difference (study eye IOP minus fellow eye IOP) 510 0.5 (2.2) 0.2 (1.9) 0.2 (1.9)
IOP, intraocular pressure.
Figure 1 Model for spikes in postinjection IOP (postinjection minus preinjection) in the study eye. Plot of the effects of covariates on IOP spikes in
injected study eyes. The point estimates and 95% CIs are shown. FE, fellow eye; IOP, intraocular pressure; OU, both eyes; SE, study eye.
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Outcome 3: difference in preinjection IOP between study
and fellow eyes during time in study (study eye minus
fellow eye)
Preinjection IOP was measured in both eyes for 13 208 (98.8%)
of the 13 371 attended study visits. Data were available for 606
patients at visit 0 and 510 patients at visit 24.
Figure 3 shows the multivariable effect estimates of the cov-
ariates. The difference between IOP in the two eyes increased
over time (0.01 mm Hg/month) with higher readings from the
study eye compared with the fellow eye. Longer time intervals
between injections reduced the difference in IOP between the
study and fellow eye (−0.02 mm Hg). Cataract surgery on the
Figure 2 Model for preinjection IOP in the study eye. Plot of the effects of covariates on preinjection IOP in the study eye. The point estimates and
95% CIs are shown. FE, fellow eye; IOP, intraocular pressure; OU, both eyes; SE, study eye.
Figure 3 Model for difference in preinjection IOP between the study and fellow eyes (study eye minus fellow eye). Plot of the effects of covariates
on difference in IOP between study and fellow eye. The point estimates and 95% CIs are shown. FE, fellow eye; IOP, intraocular pressure; SE, study
eye.
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study eye and glaucoma in any eye signiﬁcantly reduced the dif-
ference in preinjection IOP between eyes (−0.51 and
−0.67 mm Hg, respectively) while that on the fellow eye signiﬁ-
cantly increased the difference (0.77 mm Hg). Mean arterial
pressure, baseline IOP in the study eye, study drug, age at ran-
domisation and gender did not have a statistically signiﬁcant
effect on the difference in preinjection IOP between the two
eyes (p=0.27, p=0.22, p=0.87, p=0.096 and p=0.89,
respectively).
DISCUSSION
This exploratory analysis on the IVAN trial data has demon-
strated a statistically signiﬁcant increase with time in trial of the
preinjection IOP (both study eye only and intereye difference
analyses) and the immediate postinjection IOP change in study
eyes that received anti-VEGF therapy. It should be noted that
the study population was patients with treatment naive nAMD,
of whom less than 10% had glaucoma; investigators were dis-
couraged from recruiting patients with advanced glaucoma.
Accordingly, the results of this should not be extrapolated to
those with advanced glaucoma.
In our models, we chose time in trial as a proxy for number
of injections (we could not ﬁt both as they were highly corre-
lated). In the models dealing with IOP spike and preinjection
IOP over time in the study eye, this effect also includes changes
with age within patients (which is distinct from the cross-
sectional effect of age between patients) since patients were
ageing with time in trial. The third analysis, of changes in the
intereye difference in IOP over time, provides the most direct
estimate of the trend in IOP over time attributable to the
number of injections, since ageing cannot be a consideration (ie,
both eyes age at the same time).
The ﬁrst model explored was the immediate postinjection
IOP change. An injection of even a small volume into the vitreous
gives an immediate rise in the IOP, and injections of anti-VEGF
agents are no exception9 14–16 given the non-extensible properties
of the sclera. This pressure rise usually returns to normal in
under 1 h without the need for pressure lowering treatment, and
therefore our analyses were adjusted for the varying time of the
postinjection measurement after administration of the injection.
As adjustment of IOP following a volume load occurs as a
consequence of pressure dependent increased ﬂow through the
trabecular meshwork (the uveoscleral pathway ﬂux is independent
of the ocular pressure), we predicted that damage to the trabecu-
lar meshwork would give rise to an elevated and more prolonged
postinjection IOP rise. Kahook et al17 raised this as a particular
concern for repackaged bevacizumab due to the presence of
increased levels of particulates associated with repackaging. Our
data found no difference between those receiving ranibizumab
and those receiving repackaged bevamizumab arguing against an
association between repackaging and pressure rises.
Consistent with previous reports, a small (1.15 mm Hg)
increase in the pressure rise in study eyes of patients with glau-
coma15 compared with those without glaucoma was observed. A
reduction in IOP of similar size (1 mm Hg) is seen in
cataract-operated versus unoperated study eyes. Fluid has to
ﬂow past the lens from the vitreous cavity to the anterior
chamber and then into the angle and out through the trabecular
meshwork. Intraocular lenses, due to their smaller size, reduce
the resistance to this ﬂow. We would have expected the same
effect when both eyes were pseudo/aphakic and it is a matter of
surprise that this was not observed.
On average the IOP spike increased at a rate of 0.03 mm Hg/
month in the trial, which over the 24-month period equates to a
rise of 0.72 mm Hg. There was no suggestion that the IOP
increase was higher with bevacizumab.
In the second model, we explored whether a rise in the prein-
jection IOP would occur in the study eye over time. Three sig-
niﬁcant factors emerged. The ﬁrst was phakic status, with our
ﬁndings being consistent with previous observations that cataract
surgery causes a lowering of the ocular pressure.18
After allowance for cataract surgery, age and glaucoma, there
was a small (0.02 mm Hg/month) signiﬁcant rise in IOP over
time but no relationship with the agent injected.
We repeated the analysis excluding blood pressure from the
model as 0.023 mm Hg rise in IOP per mm Hg rise in blood
pressure has been shown19 and is 0 similar to the 0.01 mm Hg
noted in the present study. Anti-VEGF agents can cause a rise in
blood pressure, and if the mechanism for their effect on the
ocular pressure is mediated by this effect on the blood pressure,
then controlling for blood pressure would reduce or eliminate
this effect. We checked this and the relationship remained
unchanged arguing for a local effect rather than a systemic
action.
As IOP tends to rise with age, we constructed a third model
using the fellow eye as an internal control, which removes the
effect of in-trial ageing. Again, cataract surgery and glaucoma
appeared in the model in a manner consistent with the previous
analyses. The rise in IOP was similar to that observed in the pre-
vious model supporting our ﬁndings of a small but signiﬁcant
rise in IOP with injection frequency. As with the other models,
there was no difference between the anti-VEGF drugs.
Overall, our data support an ocular hypertensive action of
anti-VEGF drugs probably mediated by a direct action on the
trabecular meshwork. The endothelial cells are known to express
VEGF receptors and endothelial nitric oxide synthase, and one
potential mechanism for the observed rise in the IOP is inhibition
of the ocular hypotensive VEGF-NO pathway.20 There was no
indication of differential effects on IOP between ranibizumab and
bevacizumab.
The effect on IOP is small but discernible due to the size of
this trial. As anti-VEGF therapies require long administration,
information on the potential risk of high IOP spikes and
chronic IOP elevation becomes increasingly relevant. The other
studies that have failed to identify the change in IOP that occurs
in eyes treated with anti-VEGF agents have generally had small
sample sizes and short-term follow-up.1 4 We cannot comment
on the risk of developing glaucomatous optic neuropathy (disc
appearances were not graded) but the limited evidence available
from the literature so far is reassuring.21–24 Nonetheless, a note
of caution should be struck as endothelial damage from radi-
ation is a potentially late complication (reﬂecting the slow turn-
over rate of endothelial cells) and can take 3 years to manifest25
and a similar situation may apply here.
We conclude that repeated use of anti-VEGF agents induces a
small but statistically signiﬁcant rise in IOP in treated eyes.
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